1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.

2. Reaven GM. Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 604-615.

3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.

4. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabet Rev 1997; 5:177-269.

5. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299:853-855.

6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999; 281:2005-2012.

7. Lebovitz HE. Insulin Secretogogues. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 769-778.

8. Groop LC. Drug treatment of non-insulin-dependent diabetes mellitus. In: Pickup JC, Williams G, editors. Textbook of Diabetes. London: Blackwell, 1998: 1-18.

9. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303.

10. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001; 52:239-257.

11. Matthaei S, Stumvoll M, Kellerer M, Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21:585-618.

12. Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials. Diabetes Metab 1998; 24:311-320.

13. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002; 287(3):360-372.

14. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411.

15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.

16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.

17. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care 1998; 21:1167-1172.

18. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;(129):5-11.

19. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29(8):1963-1972.

20. The American Association of Clinical Endocrinologists. Implementation conference for ACE outpatient diabetes mellitus consensus conference recommendations: position statement. Article Online 2005; http://www.aace.com/pub/pdf/guidelines/OutpatientImplementationPositionStatement.pdf.

21. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29:2137-2139.

22. Guillam MT, Dupraz P, Thorens B. Glucose uptake, utilization, and signaling in GLUT2-null islets. Diabetes 2000; 49:1485-1491.

23. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45:223-241.

24. Meglasson MD, Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev 1986; 2:163-214.

25. Inagaki N, Gonoi T, Clement JP et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270:1166-1170.

26. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 2000; 133:73-74.

27. Turner RC, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124:136-145.

28. Dunning BE, Foley JE. New therapies to increase insulin secretion. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 836-842.

29. Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001; 7:1375-1397.

30. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345-351.

31. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic b-cells. Am J Physiol 1995; 268:E185-E193.

32. Weaver ML, Orwig BA, Rodriguez LC et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001; 29:415-421.

33. Hatorp V, Huang WC, Strange P. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. J Clin Endocrinol Metab 1999; 84:1475-1478.

34. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61:1625-1660.

35. Goldberg RB, Einhorn D, Lucas CP et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21:1897-1903.

36. Marbury T, Huang WC, Strange P, Lebovitz HE. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43:155-166.

37. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22:119-124.

38. Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000; 23:979-983.

39. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108:151-163.

40. Levien TL, Baker DE, Campbell RK, White JR, Jr. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001; 35:1426-1434.

41. Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24:983-988.

42. Kahn SE, Montgomery B, Howell W et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86:5824-5829.

43. Horton ES, Clinkingbeard C, Gatlin M, Foley JE, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660-1665.

44. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well- controlled type 2 diabetic patients. Diabetes Care 1999; 22:789-794.

45. Bailey CJ, Day C. Traditional plant medicine as treatments for diabetes. Diabetes Care 1989; 12:553-564.

46. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.

47. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102:99-110.

48. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38:387-395.

49. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New England J Med 1995; 333:550-554.

50. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6:89-131.

51. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-1174.

52. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998; 67:821-855.

53. Turner RC, Holman RR, Stratton IM et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.

54. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541-549.

55. Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents. II. Synthesis of 5-[4-(1- methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull 1982; 30:3580-3600.

56. Sohda T, Ikeda H, Meguro K. Studies on antidiabetic agents .12. Synthesis and activity of the metabolites of (+/-)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]- 2,4-thiazolidinedione (pioglitazone). Chem Pharm Bull 1995; 43:2168-2172.

57. Greene DA. Rosiglitazone: a new therapy for type 2 diabetes. Expert Opin Investig Drugs 1999; 8:1709-1719.

58. Foyt HL, Ghazzi MN, Hanley RM, Saltiel AR, Whitcomb RW. Thiazolidinediones. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 788-797.

59. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002; 63:1-10.

60. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25:815-821.

61. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23:1792-1823.

62. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27:305-313.

63. Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1999; 1:267-275.

64. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001; 44:2210-2219.

65. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25:517-523.

66. Kawamori R, Matsuhisa M, Kinoshita J et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998; 41:35-43.

67. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45:1661-1669.

68. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-514.

69. Lehmann JM, Moore LB, Smitholiver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma(PPAR-gamma). J Biol Chem 1995; 270:12953-12956.

70. Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 1999; 54:345-367.

71. Leibowitz MD, Fievet C, Hennuyer N et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473:333-336.

72. Willson TM, Cobb JE, Cowan DJ et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39:665-668.

73. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000; 11:362-368.

74. Picard F, Auwerx J. PPARg and glucose homeostasis. Annu Rev Nutr 2002; 22:167-197.

75. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409-435.

76. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14:1293-1307.

77. Fajas L, Auboeuf D, Raspe E et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem 1997; 272:18779-18789.

78. Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 48:1319-1327.

79. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143:998-1007.

80. de Souza CJ, Eckhardt M, Gagen K et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50:1863-1871.

81. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51:7-18.

82. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947-953.

83. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.

84. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25:376-380.

85. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13:51-59.

86. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13:18-23.

87. Sood V, Colleran K, Burge MR. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000; 2:429-440.

88. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 2002; 18 (Suppl 2):S16-S22.

89. Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24:378-396.

90. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21:1082-1099.

91. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60:333-343.

92. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280-288.

93. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:308-315.

94. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000; 283:1695-1702.

95. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio BJ et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18:127-134.

96. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605-1611.

97. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22:1395-1409.

98. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111:10-17.

99. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24:710-719.

100. Gorson DM. Significant weight gain with rezulin therapy. Arch Intern Med 1998; 159:99.

101. Anonymous. Physicians' Desk Reference: PDR. Montvale, NJ: Medical Economics Press, 2002.

102. Lebovitz HE. a-Glucosidase inhibitors as agents in the treatment of diabetes. Diabet Rev 1998; 6:132-145.

103. Magner J, Amatruda JM. a-glucosidase inhibitors in the treatment of diabetes. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000.

104. Puls W. Pharmacology of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology: Oral Antidiabetics. Berlin: Springer, 1996: 497-525.

105. Martin AE, Montgomery PA. Acarbose: An alpha-glucosidase inhibitor. Amer J Health-Syst Pharm 1996; 53:2277-2290.

106. Coniff R, Krol A. Acarbose: a review of US clinical experience. Clin Ther 1997; 19:16-26.

107. Chiasson JL, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19:1190-1193.

108. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new a-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996; 45:731-737.

109. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104:517-529.

110. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414:821-827.

111. Lazar DF, Saltiel AR. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov 2006; 5:333-342.

112. Pourcet B, Fruchart JC, Staels B, Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006; 11:379-401.

113. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2006; Epub ahead of print.

114. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142:521-527.

115. Ahren B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 1998; 20:642-651.

116. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47:1663-1670.

117. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47:764-769.

118. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999; 38:11597-11603.

119. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2002; 45:2362-2365.

120. Deacon CF, Ahren B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004; 13:1091-1102.

121. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751:33-44.

122. Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54:2988-2994.

123. Conarello SL, Li Z, Ronan J et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100:6825-6830.

124. Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 2003; 4:412-420.

125. Takasaki K, Iwase M, Nakajima T et al. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur J Pharmacol 2004; 486:335-342.

126. Sakashita H, Kitajima H, Nakamura M, Akahoshi F, Hayashi Y. 1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg Med Chem Lett 2005; 15:2441-2445.

127. Sakashita H, Akahoshi F, Kitajima H, Tsutsumiuchi R, Hayashi Y. [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. Bioorg Med Chem 2006; 14:3662-3671.

128. Augeri DJ, Robl JA, Betebenner DA et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48:5025-5037.

129. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42:1324-1331.

130. Mitani H, Takimoto M, Hughes TE, Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn J Pharmacol 2002; 88:442-450.

131. Mitani H, Takimoto M, Kimura M. Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged fischer 344 rats lacking its enzyme activity. Jpn J Pharmacol 2002; 88:451-458.

132. Ahren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25:869-875.

133. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46:2774-2789.

134. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006; 15:431-442.

135. Ristic S, Bates PC. Vildagliptin: A novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs Today (Barc ) 2006; 42:519-531.

136. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38:423-428.

137. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:2078-2084.

138. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874-2880.

139. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28:1936-1940.

140. Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006; 40:1336-1343.

141. Herman G, Hanefield M, Wu M, Chen X, Zhao P, Stein P. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes (Abstract 541-P). Diabetes 2005; 54 (Suppl 1):A134.

142. Scott R, Herman G, Zhao P, Chen X, Wu M, Stein P. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D) (Abstract 41-OR). Diabetes 2005; 54 (Suppl 1):A10.

143. Brazg R, Thomas K, Zhao P, Xu L, Chen X, Stein P. Effect of adding MK-0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin (Abstract 11-OR). Diabetes 2005; 54 (Suppl 1):A3.

144. Karasik A, Charbonnel B, Liu.J., Wu M, Meehan A, Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes (Abstract 501-P). Diabetes 2006; 55 (Suppl 1):A119-A120.

145. Rosenstock J, Brazg R, Andryuk PJ, McCrary Sisk C, Lu K, Stein P. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM) (Abstract 556-P). Diabetes 2006; 55 (Suppl 1):A132.

146. Nonaka K, Kakikawa T, Sato A et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor, in Japanese patients with T2DM (Abstract 537-P). Diabetes 2006; 55 (Suppl 1):A128.

147. Di M, V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57:553-574.

148. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28:153-157.

149. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active componenet of hashish. J Am Chem Soc 1964; 86:1646-1647.

150. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27:73-100.

151. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005;(168):299-325.

152. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006; 5:272-292.

153. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134:1151-1154.

154. Kirkham TC, Williams CM, Fezza F, Di M, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136:550-557.

155. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392:147-156.

156. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB₁ cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-648.

157. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB₁ cannabinoid receptor knockout mice. Handb Exp Pharmacol 2005;(168):117-145.

158. Engeli S, Bohnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.

159. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005; 29:755-759.

160. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47:1919-1926.

161. Scheen AJ, Van Gaal LG, Despres JP, Pi-Sunyer X, Golay A, Hanotin C. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev Med Suisse 2006; 2:1916-1923.

162. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB₁ receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15:307-315.

163. Boyd ST, Fremming BA. Rimonabant--a selective CB₁ antagonist. Ann Pharmacother 2005; 39:684-690.

164. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.

165. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006; 295:761-775.

166. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.

167. Brower V. Proteomics: biology in the post-genomic era. Companies all over the world rush to lead the way in the new post-genomics race. EMBO Rep 2001; 2(7):558-560.

168. Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000; 4:445-451.

169. Toledo-Sherman LM, Chen D. High-throughput virtual screening for drug discovery in parallel. Curr Opin Drug Discov Devel 2002; 5:414-421.

170. Jhoti H. High-throughput structural proteomics using x-rays. Trends Biotechnol 2001; 19:S67-S71.

171. Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002; 1:45-54.

172. Card GL, Blasdel L, England BP et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 2005; 23:201-207.

173. Fischer HP. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Annu Rev 2005; 11:1-68.

174. Michelson S. The impact of systems biology and biosimulation on drug discovery and development. Mol Biosyst 2006; 2:288-291.

175. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-643.

176. Groop L, Widen E, Franssila-Kallunki A et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32:599-605.

177. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991; 17:224-231.

178. Reaven GM, Johnston P, Hollenbeck CB et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992; 74:1020-1026.

179. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17:1093-1099.

180. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990; 13 (Suppl 3):32-36.

181. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928-935.

182. Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 1997; 38:33-40.

183. Rosenstock J, Brown A, Fischer J et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998; 21:2050-2055.

184. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:737-745.

185. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001; 6:1747-1756.

186. Porte D, Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 2001; 17:181-188.

187. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11:351-356.